- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01599000
Artemether-Lumefantrine Clinical Effectiveness Study
In 2009, Papua New Guinea officially adopted artemether-lumefantrine (AL) as new national first-line drug for uncomplicated malaria. The principal purpose of this study is to measure the absolute effectiveness of AL when used under real-life clinical conditions, as compared to optimized in-vivo trial conditions. This question was raised by the National Department of Health in preparation for the country-wide roll-out of AL.
The study is designed as a randomized controlled trial comparing two study arms. Patients in the "effectiveness arm" receive the first dose of AL under full supervision in the clinic; the following doses will be taken at home, as in real-life clinical practice and according to the new national treatment guidelines. Patients in the "efficacy arm" will receive all doses of AL as directly observed treatment in the clinic in order to establish the efficacy of the drug when used under ideal conditions.
The study will enroll outpatients aged 6 months to 10 years with a history of fever and a positive rapid test for malaria. Patients meeting all enrollment criteria and providing full written informed consent by a parent/caretaker will be randomized into either of the two study arms. Patients in both arms will be followed up actively for 42 days. Patients in the efficacy arm will be scheduled for visits on days 0, 1, 2, 3, 7, 14, 28 and 42; patients in the effectiveness arm on days 0, 3, 7, 14, 28 and 42.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Milne Bay
-
Alotau, Milne Bay, Papua New Guinea
- Gurney Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6 months to 10 years (+/- 1 month for children without known date of birth)
- Permanent resident in the study area
- Not enrolled in another study at the same time
- No known history of hypersensitivity reactions to artemether or lumefantrine
- History of fever in the previous 72 hours (approximate)
- Rapid diagnostic test (RDT) positive for any species of Plasmodium
Exclusion Criteria:
- General danger signs: inability to drink or breastfeed, vomiting everything, recent history of convulsions, lethargy or unconsciousness, inability to sit or stand up
- Signs of severe malaria (impaired consciousness, respiratory distress, circulatory collapse, abnormal bleeding, jaundice, or as determined by clinician)
- Severe malnutrition: defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/WHO normalized reference values, or who has symmetrical oedema involving at least the feet; or middle upper arm circumference under 12 cm
- Clinically significant concomitant disease requiring admission
- Contraindications mentioned in the national treatment guidelines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Efficacy arm
Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
|
fixed-dose tablet, six doses over three days, according to weight group
Other Names:
|
Experimental: Effectiveness arm
Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
|
fixed-dose tablet, six doses over three days, according to weight group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adequate Clinical and Parasitological Response (ACPR)
Time Frame: 42 days
|
ACPR = Absence of parasitemia on Day 42 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure (adapted from WHO 2003).
|
42 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Peter M Siba, PhD, Papua New Guinea Institute of Medical Research
- Principal Investigator: Manuel W Hetzel, PhD, Papua New Guinea Institute of Medical Research
- Principal Investigator: Mueller Ivo, PhD, Walter and Eliza Hall Institute of Medical Research
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRAC.09.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parasitologically Confirmed; Malarial
-
Centre de Recherche Médicale de LambarénéInstitute of Tropical Medicine, University of TuebingenNot yet recruitingSevere Malarial TreatmentGabon
-
Sandra BucciUniversity of Edinburgh; NHS Lothian; Manchester University NHS Foundation Trust and other collaboratorsCompletedChild Sexual Abuse, Confirmed, SequelaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterWithdrawnHistologically-confirmed MalignanciesUnited States
-
Université de ParakouUniversity of Copenhagen; Hôpital Cochin; University of Ghana; Institut de Recherche... and other collaboratorsCompletedDetermine the Impact of Treatment on the Acquisition of Anti-malarial Antibodies in Children Before, During and After the Intervention | Determine the Prevalence of Malarial Infection in Children Before, During and After Seasonal Malaria ChemopreventionBenin
-
Lihir Medical CentreWithdrawnMalaria | Anaemia | Hyper-reactive Malarial SplenomegalyPapua New Guinea
-
Institut de Cancérologie de la LoireCompleted
-
Duke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingUnspecified Child Maltreatment, Suspected | Unspecified Child Maltreatment, ConfirmedUnited States
-
Novartis PharmaceuticalsTerminatedHistologically-proven and Radiologically-confirmed Solid TumorsItaly, New Zealand
-
Duke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingUnspecified Child Maltreatment, Suspected | Unspecified Child Maltreatment, ConfirmedUnited States
-
University of Texas Southwestern Medical CenterCompletedPain, Intractable | Terminally Ill | Histologically-confirmed Advanced CancerUnited States
Clinical Trials on Artemether-lumefantrine combination
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
Liverpool School of Tropical MedicineMalawi-Liverpool-Wellcome Trust Clinical Research Programme; National Malaria... and other collaboratorsUnknown
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
Centers for Disease Control and PreventionMinistry of Health, Brazil; Evandro Chagas National Institute of Infectious... and other collaboratorsCompleted
-
University of OxfordUniversity of KinshasaCompleted
-
London School of Hygiene and Tropical MedicineUniversity Medical Center Nijmegen; Centre national de recherche et de formation...Completed
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda
-
Novartis PharmaceuticalsCenters for Disease Control and PreventionCompletedMalariaUnited States